Associations of adipokines and hyperLDL-C in young adults with abdominal obesity

The aim of the study was to examine the relationships between adipokine levels and elevated low-density lipoprotein cholesterol (LDL-C) in individuals aged 25–44 years, with and without abdominal obesity (AO).
Material and methods. The study included individuals aged 25–44 years, divided into groups based on the presence/absence of AO and LDL-C levels. Anthropometric parameters, lipid profile (LDL-C, HDL-C, TG, total cholesterol), carbohydrate metabolism markers, and concentrations of certain adipokines were assessed. Statistical data processing was performed using the SPSS 13.0 software package.
Results. In all groups of individuals with LDL-C ≥ 3.0 mmol/L, atherogenic changes in the lipid profile, increased blood pressure and glucose levels were observed; however, the severity of concomitant metabolic disorders depended on the presence of AO. Levels of plasminogen activator inhibitor type 1 (PAI-1) (OR 1.010, 95 %, CI 1.000–1.019, p = 0.047) and C-peptide (OR 1.262, 95 %, CI 1.053–1.512, p = 0.012) demonstrated statistically significant associations with elevated LDL-C, regardless of WC. However, when including both molecules in the model, associations were obtained only for C-peptide (OR 1.416, 95 %, CI 1.079–1.858, p = 0.012) and age (OR 1.038, 95 %, CI 1.011–1.065, p = 0.006).
Conclusions. Young individuals with LDL-C ≥ 3.0 mmol/L are more likely to exhibit signs of metabolic dysfunction and abnormal visceral adipose tissue activity, manifested by elevated adipocytokines. In young individuals, the risk of having hyperLDL-C is associated with increasing age and elevated C-peptide and PAI-1 levels, regardless of gender or the presence of AO.

1. Kawai T., Autieri M.V., Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am. J. Physiol. Cell. Physiol., 2021; 320 (3): C375–C391. doi: 10.1152/ajpcell.00523.2020

2. Datieva L.R., Kaimtazova N.K. The role of adipokines in the development of adipose tissue inflammation in metabolic syndrome: a modern view (literature review). J. New Med. Technol., 2024; 4: 123–130. (In Russ.) doi: 10.24412/1609-2163-2024-4-123-130]

3. Shestopalov A.V., Ganenko L.A., Grigorieva T.V., Laykov A.V., Vasilev I.Yu., Kolesnikova I.M. Adipokines and myokines as indicators of obesity phenotypes and their association with gut microbiome diversity. RSMU Bull., 2023; (1): 49–58. (In Russ.) https://doi.org/10.24075/vrgmu.2023.004

4. Faulkner J.L., Belin de Chantemèle E.J. Sex hormones, aging and cardiometabolic syndrome. Biol. Sex. Differ., 2019; 10: 30. doi: 10.1186/s13293-019-0246-2

5. Rodgers J.L., Jones J., Bolleddu S.I., Vanthenapalli S., Rodgers L.E., Shah K., Karia K., Panguluri S.K. Cardiovascular risks associated with gender and aging. J. Cardiovasc. Dev. Dis. 2019; 6 (2): 19. doi: 10.3390/jcdd6020019

6. Farkhondeh T., Llorens S., Pourbagher-Shahri A.M., Ashrafizadeh M., Talebi M., Shakibaei M., Samarghandian S. An overview of the role of adipokines in cardiometabolic diseases. Molecules, 2020; 25 (22): 5218. doi: 10.3390/molecules25225218

7. ESC Committee for Practice Guidelines; ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019; 290: 140–205. doi: 10.1016/j.atherosclerosis.2019.08.014

8. Chalitsios C.V., Akyea R.K., Abdul-Hamid H., LeonardiBee J., Kanchau J.D., Kamal A., Mohamed-Yassin M.S., Baharudin N., Ramli A.S., Qureshi N. Age and sex differences in LDL cholesterol distribution in adults in Malaysia: a cross-sectional study (2010–2021). Int. J. Gen. Med., 2023; 16: 5885–5888. doi: 10.2147/IJGM.S423091

9. Fedorovich A.A., Drapkina O.M., Eliashevich S.O., Shoibonov B.B., Sukhinina N.Yu., Lavrenova E.A. Association of multiple modified low-density lipoproteins with obesity. Russ. J. Preventive Medicine, 2018; 21 (6): 118–123. (In Russ.) https://doi.org/10.17116/profmed201821061118

10. Zheng C., Liu Y., Xu C., Zeng S., Wang Q., Guo Y., Li J., Li S., Dong M., Luo X., Wu Q. Association between obesity and the prevalence of dyslipidemia in middle-aged and older people: an observational study. Sci. Rep., 2024; 14: 11974. doi: 10.1038/s41598-024-62892-5

11. Ezhov M.V., Batluk T.I., Tomkin D.S., Tsyplukhina E.F., Arutyunov A.G. Prevalence of dyslipidemia before and during the COVID-19 pandemic. Atherosclerosis and Dyslipidemias, 2023; 2 (51): 31–42. (In Russ.) https://doi.org/10.34687/2219-8202

12. Bays H.E., Kirkpatrick C.F., Maki K.C., Toth P.P., Morgan R.T., Tondt J., Christensen S.M., Dixon D.L., Jacobson T.A. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association. J. Clin. Lipidol., 2024; 18 (3): e320–e350. doi: 10.1016/j.jacl.2024.04.001

13. Levine J.A., Oleaga C., Eren M., Amaral A.P., Shang M., Lux E., Khan S.S., Shah S.J., Omura Y., Pamir N., Hay J., Barish G., Miyata T., Tavori H., Fazio S., Vaughan D.E. Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci. Rep., 2021; 11: 430. doi: 10.1038/s41598-020-79948-x

14. Li Y., Zhao D., Li Y., Meng L., Enwer G. Serum C-peptide as a key contributor to lipid-related residual cardiovascular risk in the elderly. Arch. Gerontol. Geriatr., 2017; 73: 263–268. doi: 10.1016/j.archger.2017.05.018

15. Xu Z., Huang Y. Blood PAI-1 and cardiovascular and metabolic risk factors among middle-aged women: results from the SWAN study. Sci Rep., 2024; 14: 21207. doi: 10.1038/s41598-024-71908-z

16. Dannecker C., Wagner R., Peter A., Hummel J., Vosseler A., Häring H.U., Fritsche A., Birkenfeld A.L., Stefan N., Heni M. Low-density lipoprotein cholesterol is associated with insulin secretion. J. Clin. Endocrinol. Metab., 2021; 106 (6): 1576–1584. doi: 10.1210/clinem/dgab147